10x Genomics Stock Surges 21%, With A 5-Day Winning Spree
10x Genomics (TXG) – a provider of single cell gene expression analysis instruments and consumables – hit a 5-day winning streak, with cumulative gains over this period amounting to 21%. The company’s market cap has surged by about $452 Mil over the last 5 days and currently stands at $2.7 Bil.
Is this opportunity or trap? There are a few things to fear in TXG stock given its overall Weak operating performance and financial condition. This isn’t appropriately reflected in the stock’s Moderate valuation which is why we think it is Unattractive (For details, see Buy or Sell TXG).
But here is the interesting part. You are reading about this 21% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Robinhood Stock: The Multiple Tells The Wrong Story
- How ISRG Just Secured The U.S. Market
- How UNH Stock Is Trading Short-Term Margins For Long-Term Moats
- Key Metrics To Track For Capital One After Its Q1 Earnings Miss
- Marvell Stock: The Good News Keeps Coming
- Fifth Third Earnings: Adjusted EPS Beats Despite Revenue Miss And Acquisition.
The following table summarizes the return for TXG stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TXG | S&P 500 |
|---|---|---|
| 1D | 5.6% | 0.0% |
| 5D (Current Streak) | 20.5% | -1.0% |
| 1M (21D) | 9.5% | -4.8% |
| 3M (63D) | 23.4% | -4.7% |
| YTD 2026 | 28.2% | -4.2% |
| 2025 | 13.6% | 16.4% |
| 2024 | -74.3% | 23.3% |
| 2023 | 53.6% | 24.2% |
However, big gains can follow sharp reversals – but how has TXG behaved after prior drops? See TXG Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 160 S&P constituents with 3 days or more of consecutive gains and 35 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 128 | 14 |
| 4D | 12 | 8 |
| 5D | 18 | 1 |
| 6D | 0 | 6 |
| 7D or more | 2 | 6 |
| Total >=3 D | 160 | 35 |
Key Financials for 10x Genomics (TXG)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $610.8 Mil | $642.8 Mil |
| Operating Income | $-194.6 Mil | $-110.9 Mil |
| Net Income | $-182.6 Mil | $-43.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $149.0 Mil | $166.0 Mil |
| Operating Income | $-32.2 Mil | $-19.5 Mil |
| Net Income | $-27.5 Mil | $-16.3 Mil |
While TXG stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.